Maura L. Gillison
The University of Texas MD Anderson Cancer Center, The Ohio State University
Papers
3
Total Citations
112
H-Index
2
About
Maura L. Gillison is a leading oncologist and epidemiologist whose groundbreaking research has transformed the understanding and treatment of human papillomavirus (HPV)-related head and neck cancers, particularly oropharyngeal squamous cell carcinoma. Her work has been pivotal in establishing p16 positivity as a critical biomarker for prognosis and treatment de-escalation. Dr. Gillison’s major contributions include leading the landmark ECOG-ACRIN E3311 trial, which demonstrated that de-intensified postoperative radiotherapy (50 Gy) can achieve excellent two-year progression-free survival in intermediate-risk p16+ oropharynx cancer patients, potentially reducing long-term toxicity without compromising outcomes. This trial, cited over 100 times, also pioneered a novel surgeon credentialing and quality assurance process to standardize transoral robotic surgery. Her research further explores the toxicity and swallowing outcomes of intensity-modulated proton therapy, aiming to improve quality of life for survivors. With a career spanning over two decades, Dr. Gillison’s work has reshaped clinical guidelines and inspired a generation of researchers to pursue precision oncology in head and neck cancers, making her one of the most influential figures in the field.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3